



## August 2018 Newsletter

Volume 6 Issue 8

### A Letter from the Founder, Dr. Christine Brezden-Masley

Thank you for your continued support of the website and use of the e-referral clinical trial portal.

Our main goal is to showcase as many oncology clinical trials that are open in the province, providing ready access for your patients.

Simply send us an email with any suggestions you may have, as we are always striving to improve the service of the CCTC.

Sincerely,

**Dr. Christine Brezden-Masley**

### A Letter from the Project Manager, Alexandra Moskalewicz

Hello CCTC members,

Please contact me if I can be of any assistance in posting any new trials, or removing those from the website that have recently closed to accrual at your centre, as the CCTC only features open trials.

As well, feel free to share this newsletter with your colleagues in oncology, as we are always happy new members join the network!

Kind Regards,

**Alexandra Moskalewicz**

## ARTICLE RECOMMENDATION

### Are phase I trials safe for older patients?

Baldini C., Le Saux O., Helissey C., Aspeslagh S., Castanon E., Varga A., Gazzah A., Bahleda R., Mir O., Massard C., Soria JC., Hollebecque A

DOI: [10.1016/j.jgo.2017.08.012](https://doi.org/10.1016/j.jgo.2017.08.012) Published March 2018

#### ABSTRACT:

Phase I clinical trials in oncology primarily aim to assess the toxicity profile of new drugs and determine recommended phase II doses (RP2D). Since the cancer rate increases with age and our population is continually aging, RP2D must necessarily be assessed in older patients. Few clinical studies include older patients, however, and particularly few Phase I trials. We reviewed published data on the safety and efficacy of Phase I trials in older patients. The majority of studies included primarily young, fit patients, with age thresholds varying widely from 65 to 80 years. However, age does not seem to be associated with more toxicity or less efficacy. While Phase I trials seem feasible in fit older patients, geriatric-medicine score systems should be included in the clinical trial design in order to better characterize this population.

## TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	GI	GU	GYNE	Head & Neck	Heme	Lung	Mel	Skin	Total
Imaging Study		1		1			1				3
Observational	2	3	1	1			1				8
Prevention			1				1				2
Radiation	1	2	3	6		1		5			17
Supportive Care	1	5									6
Surgical Therapy		1		1	1	1					4
Systemic Therapy	2	8	18	14	6	3	12	11	3	1	78
Therapeutic				2			2				4
<b>TOTAL</b>	<b>6</b>	<b>20</b>	<b>23</b>	<b>24</b>	<b>7</b>	<b>5</b>	<b>17</b>	<b>16</b>	<b>3</b>	<b>1</b>	<b>122</b>



## August 2018 Newsletter

Volume 6 Issue 8

### TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	<a href="#">ABC</a>	A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (MAC.21)	<ul style="list-style-type: none"> <li>• HER2 Negative</li> <li>• Adjuvant Therapy</li> </ul>	Odette Cancer Centre
GU	<a href="#">IND.223</a>	A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> <li>• Prostate Cancer</li> </ul>	London Health Sciences Centre
Heme	<a href="#">Incyte Citadel 203</a>	A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3K $\delta$ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)	<ul style="list-style-type: none"> <li>• Relapsed or Refractory Follicular Lymphoma</li> <li>• Systemic Therapy</li> </ul>	Odette Cancer Centre
GYNE	<a href="#">Empower</a>	An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma	<ul style="list-style-type: none"> <li>• Platinum-Refractory Cervical Carcinoma</li> <li>• Systemic Therapy</li> </ul>	London Health Sciences Centre
Lung	<a href="#">Merck PEARLS</a>	A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)	<ul style="list-style-type: none"> <li>• Non-Small Cell Lung Cancer</li> <li>• Systemic Therapy</li> </ul>	Royal Victoria Regional Health Centre
Any Malignancy	<a href="#">B9991023</a>	A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies	<ul style="list-style-type: none"> <li>• 1st line</li> <li>• Systemic Therapy</li> </ul>	Kingston General Hospital
GI	<a href="#">CanStem 111P</a>	A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	<ul style="list-style-type: none"> <li>• Metastatic Pancreatic Adenocarcinoma</li> <li>• Systemic Therapy</li> </ul>	St. Michael's Hospital



[Click here to NOMINATE your trial for Trials of the Month!](#)



## MEMBERSHIP UPDATES

**291 members**

**31 institutions**

**122 accruing trials**



## ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



## CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street  
Toronto, ON Canada  
M5B 1W8

[cometrials@smh.ca](mailto:cometrials@smh.ca)

(416) 809-3915

[www.cometrials.com](http://www.cometrials.com)

## INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	3
Grand River Hospital	Waterloo	9	1
Humber River Regional Hospital	Toronto	5	2
Kingston General Hospital	Kingston	4	36
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	21	-
London Health Sciences Centre	London	12	54
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	-
Michael Garron Hospital	Toronto	7	3
Mount Sinai Hospital	Toronto	2	1
North York General Hospital	Toronto	15	3
Odette Cancer Centre/Sunnybrook	Toronto	62	48
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	26	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	24	14
Scarborough General Hospital	Toronto	3	-
Southlake Regional Health Centre	Newmarket	21	8
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	14	4
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Trillium Health Partners	Mississauga	17	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	2	-
Wingham and District Hospital	Wingham	1	-